BridgeBio Pharma (BBIO) PT Raised to $110 at TD Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BBIO Hot Sheet
Price: $69.37 +1.79%
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 18
Rating Summary:
25 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 10 | Down: 17 | New: 18
Join SI Premium – FREE
TD Cowen analyst Tyler Van Buren raised the price target on BridgeBio Pharma (NASDAQ: BBIO) to $110.00 (from $95.00) while maintaining a Buy rating.
You May Also Be Interested In
- Canaccord Downgrades Botanix Pharmaceuticals Ltd (BOT:AU) to Hold
- West Fraser Timber Co Ltd (WFG:CN) (WFTBF) PT Raised to Cdn$101 at CIBC
- Amotiv Ltd (AOV:AU) PT Lowered to AUD9.90 at Canaccord
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
